Abivax SA Sponsored ADR $ABVX Shares Sold by Velan Capital Investment Management LP

Velan Capital Investment Management LP lowered its holdings in Abivax SA Sponsored ADR (NASDAQ:ABVX) by 14.8% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 65,630 shares of the company’s stock after selling 11,370 shares during the period. Abivax comprises 5.3% of Velan Capital Investment Management LP’s holdings, making the stock its 7th biggest holding. Velan Capital Investment Management LP’s holdings in Abivax were worth $8,746,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Nan Fung Trinity HK Ltd. boosted its holdings in Abivax by 11.8% during the fourth quarter. Nan Fung Trinity HK Ltd. now owns 113,365 shares of the company’s stock worth $15,288,000 after buying an additional 12,000 shares in the last quarter. Brummer Multi Strategy AB bought a new position in shares of Abivax in the fourth quarter valued at $1,939,000. Seven Fleet Capital Management LP lifted its position in shares of Abivax by 218.9% during the 1st quarter. Seven Fleet Capital Management LP now owns 43,052 shares of the company’s stock valued at $4,794,000 after acquiring an additional 29,553 shares during the last quarter. Militia Capital Management LLC acquired a new stake in shares of Abivax during the 1st quarter valued at $1,893,000. Finally, Candriam S.C.A. bought a new stake in shares of Abivax during the 1st quarter worth $4,015,000. 47.91% of the stock is currently owned by institutional investors.

Abivax Stock Performance

Shares of ABVX opened at $113.67 on Wednesday. Abivax SA Sponsored ADR has a 52 week low of $69.81 and a 52 week high of $148.83. The company has a market capitalization of $9.92 billion, a PE ratio of -21.82 and a beta of 0.97. The company’s 50 day moving average price is $124.95 and its 200 day moving average price is $118.88.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on ABVX shares. Weiss Ratings restated a “sell (d-)” rating on shares of Abivax in a report on Friday, July 17th. HC Wainwright reiterated a “buy” rating on shares of Abivax in a research report on Tuesday, June 30th. Wall Street Zen raised Abivax from a “sell” rating to a “hold” rating in a research note on Saturday, May 23rd. Wedbush boosted their price objective on Abivax from $90.00 to $110.00 and gave the stock a “neutral” rating in a report on Tuesday, June 30th. Finally, Truist Financial upped their price objective on shares of Abivax from $135.00 to $155.00 and gave the company a “buy” rating in a research note on Thursday, July 2nd. Thirteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $156.50.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.